About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker PFE · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate C…
NCT03460977 · Metastatic Castration Resistant Prostate Cancer (mCRPC), Sm…
Mevrometostat (PF-06821497), Enzalutamide
PFE
Pfizer
Phase 1Recruiting453Apr 20, 2028Registry ↗
Nov 12, 2026A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment
NCT07933848 · Renal Impairment, Healthy Adults
Prifetrastat
PFE
Pfizer
Phase 1Not yet recruiting24May 21, 2028Registry ↗
Nov 12, 2026A Study to Learn How Different Amounts of the Study Medicine Called PF-08166744 Are Tolerated and A…
NCT07933835 · Healthy Participants
PF-08166744, Placebo
PFE
Pfizer
Phase 1Not yet recruiting82Jan 18, 2028Registry ↗
Nov 12, 2026The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women W…
NCT07932925 · Urinary Incontinence, Stress, Overweight and/or Obesity
Berobenatide, Placebo
PFE
Pfizer
Phase 3Not yet recruiting900Oct 13, 2028Registry ↗
Nov 12, 2026A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococ…
NCT07794748 · Pneumococcal Disease
PG4 Multivalent Vaccine, PG4 Multivalent Vaccine
PFE
Pfizer
Phase 3Active, not recruiting
was recruiting
4,701Apr 26, 2027Registry ↗
Nov 12, 2026A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
NCT07765888 · Atopic Dermatitis
Tilrekimig, Placebo
PFE
Pfizer
Phase 3Recruiting375Mar 10, 2028Registry ↗
Nov 12, 2026A Study of MET233 in Individuals With Obesity or Overweight
NCT07022977 · Obesity and Overweight
MET233, Placebo
PFE
Pfizer
Phase 1Completed145May 28, 2026Registry ↗
Nov 12, 2026A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate…
NCT06807268 · Eczema
Abrocitinib, Placebo
PFE
Pfizer
Phase 3Active, not recruiting
was recruiting
151May 2, 2027Registry ↗
Nov 12, 2026This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus P…
NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Sigvotatug Vedotin, Pembrolizumab
PFE
Pfizer
Phase 3Recruiting714Sep 5, 2028Registry ↗
Nov 12, 2026A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in I…
NCT06587035 · Dwarfism, Pituitary
Somatrogon
PFE
Pfizer
—Recruiting50Sep 5, 2028Registry ↗
Nov 12, 2026A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
NCT06294925 · Colitis, Ulcerative
Etrasimod
PFE
Pfizer
—Active, not recruiting360May 13, 2027Registry ↗
Nov 12, 2026MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple…
NCT06152575 · Multiple Myeloma
Elranatamab, Elotuzumab
PFE
Pfizer
Phase 3Recruiting492Aug 26, 2026Registry ↗
Nov 12, 2026A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Sta…
NCT06072183 · Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Ritlecitinib, Ritlecitinib
PFE
Pfizer
Phase 3Active, not recruiting1,571Jul 30, 2027Registry ↗
Nov 12, 2026ATGAM General Investigation
NCT06039020 · Aplastic Anemia
Anti-human thymocyte immunoglobulin, equine
PFE
Pfizer
—Active, not recruiting1Mar 26, 2027Registry ↗
Nov 12, 2026A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne…
NCT05689164 · Duchenne Muscular Dystrophy
fordadistrogene movaparvovec
PFE
Pfizer
Phase 3Terminated7Sep 24, 2025Registry ↗
Nov 12, 2026Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
NCT05650476 · Metastatic Castration-Resistant Prostate Cancer
Talazoparib
PFE
Pfizer
—Available——Registry ↗
Nov 10, 2026A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants Wi…
NCT07890597 · Early Breast Cancer, Estrogen Receptor Positive (ER+), Huma…
Atirmociclib, giredestrant
PFE
Pfizer
Phase 3Not yet recruiting3,800Apr 13, 2032Registry ↗
Nov 10, 2026A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting P…
NCT07228390 · Hidradenitis Suppurativa
Ritlecitinib, Placebo
PFE
Pfizer
Phase 2Active, not recruiting128Dec 8, 2026Registry ↗
Nov 10, 2026Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449 · Liposarcoma, Prostate Cancer
PF-07220060, Letrozole
PFE
Pfizer
Phase 2Recruiting430Oct 7, 2029Registry ↗
Nov 9, 2026A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple…
NCT07927023 · Multiple Myeloma
Elranatamab, Standard of Care
PFE
Pfizer
—Not yet recruiting1Feb 1, 2027Registry ↗
Nov 9, 2026A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate H…
NCT07923981 · Hemophilia A or B
marstacimab
PFE
Pfizer
Phase 3Recruiting95Jul 2, 2029Registry ↗
Nov 6, 2026A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathi…
NCT07881757 · Apnea, Sleep Disorders
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting
was not yet recruiting
258Jun 1, 2028Registry ↗
Nov 6, 2026A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the…
NCT07876531 · Overweight and/or Obesity, Healthy Participants
Berobenatide
PFE
Pfizer
Phase 1Recruiting
was not yet recruiting
144Apr 6, 2027Registry ↗
Nov 6, 2026A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo…
NCT07874633 · Obesity, Overweight
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting
was not yet recruiting
432Jun 6, 2028Registry ↗
Nov 6, 2026A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults Wi…
NCT07845513 · Overweight, Obesity
PF-08653944
PFE
Pfizer
Phase 1Active, not recruiting
was not yet recruiting
11Feb 21, 2027Registry ↗
Nov 6, 2026Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
NCT07839871 · Respiratory Syncytial Virus (RSV)
RSVpreF, Placebo
PFE
Pfizer
Phase 3Recruiting
was not yet recruiting
920Mar 30, 2031Registry ↗
Nov 6, 2026Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Ana…
NCT07821216 · Alopecia Areata
ritlecitinib
PFE
Pfizer
—Active, not recruiting1Nov 20, 2026Registry ↗
Nov 6, 2026A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults Wit…
NCT07794774 · Obesity
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting
was not yet recruiting
197Feb 21, 2029Registry ↗
Nov 6, 2026A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
NCT07783425 · Atopic Dermatitis
Tilrekimig, Dupilumab
PFE
Pfizer
Phase 3Recruiting1,375Sep 8, 2028Registry ↗
Nov 6, 2026A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
NCT07573462 · Pneumococcal Disease
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
PFE
Pfizer
Phase 3Recruiting2,400Dec 30, 2028Registry ↗
Nov 6, 2026A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyo…
NCT07494656 · ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
tafamidis 61mg (based on prescription data)
PFE
Pfizer
—Active, not recruiting1Nov 30, 2026Registry ↗
Nov 6, 2026Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Popul…
NCT07177209 · Ulcerative Colitis
Non-Interventional Study
PFE
Pfizer
—Completed
was active, not recruiting
4,000Oct 30, 2026Registry ↗
Nov 6, 2026A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhib…
NCT07161687 · Hemophilia A or B
Marstacimab
PFE
Pfizer
—Active, not recruiting50Mar 28, 2030Registry ↗
Nov 6, 2026A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Sev…
NCT07029711 · Severe Alopecia Areata
Ritlecitinib higher dose, Ritlecitinib lower dose
PFE
Pfizer
Phase 3Active, not recruiting208Dec 2, 2026Registry ↗
Nov 6, 2026A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asth…
NCT06977581 · Asthma
PF-07275315, Placebo
PFE
Pfizer
Phase 2Recruiting252Mar 8, 2027Registry ↗
Nov 6, 2026Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109 · Alopecia Areata
Ritlecitinib
PFE
Pfizer
—Active, not recruiting450Apr 15, 2028Registry ↗
Nov 6, 2026A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
NCT06524414 · Pneumococcal Disease
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
PFE
Pfizer
Phase 2Active, not recruiting605Mar 4, 2027Registry ↗
Nov 6, 2026Litfulo Capsules Special Investigation
NCT06279221 · Alopecia Areata
LITFULO
PFE
Pfizer
—Active, not recruiting664Jan 18, 2030Registry ↗
Nov 6, 2026A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 · Pneumococcal Disease
Multivalent Pneumococcal Vaccine - Formulation 1, Multivale…
PFE
Pfizer
Phase 1/2Completed1,710May 12, 2026Registry ↗
Nov 6, 2026An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232 · Ulcerative Colitis
Etrasimod
PFE
Pfizer
Phase 3Active, not recruiting896Jun 19, 2029Registry ↗
Nov 5, 2026A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight o…
NCT07919678 · Obesity, Overweight
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting656Aug 22, 2028Registry ↗
Nov 5, 2026A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe As…
NCT07869043 · Asthma
tilrekimig, Placebo
PFE
Pfizer
Phase 3Recruiting1,100Jun 7, 2029Registry ↗
Nov 5, 2026A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to H…
NCT07845500 · Obesity, Overweight and/or Obesity
Semaglutide, Berobenatide
PFE
Pfizer
Phase 3Recruiting660Feb 16, 2028Registry ↗
Nov 5, 2026A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathi…
NCT07823608 · Apnea, Sleep Disorders
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting258Apr 30, 2028Registry ↗
Nov 5, 2026A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With…
NCT07794761 · Obesity
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting180Mar 14, 2029Registry ↗
Nov 5, 2026A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo…
NCT07792954 · Obesity, Overweight
Berobenatide, Placebo
PFE
Pfizer
Phase 3Recruiting300Mar 14, 2028Registry ↗
Nov 5, 2026A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults Wit…
NCT07725809 · Overweight, Obesity
PF-08653945
PFE
Pfizer
Phase 1Active, not recruiting
was recruiting
57Jan 13, 2027Registry ↗
Nov 5, 2026A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweig…
NCT07595549 · Obesity, Overweight and/or Obesity
PF-08653944, Placebo
PFE
Pfizer
Phase 3Recruiting954May 4, 2028Registry ↗
Nov 5, 2026A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932 · Overweight, Obesity
PF-08653945, PF-08653944
PFE
Pfizer
Phase 2Active, not recruiting940Aug 4, 2027Registry ↗
Nov 5, 2026Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655 · Non-Small-Cell Lung, Esophageal Cancer
PF-08046033
PFE
Pfizer
Phase 1Recruiting250Jul 14, 2028Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances